Studying Skin Cells to Understand Scleroderma
Examines skin fibroblast cells from adults with scleroderma to learn how the disease develops.
Plain-language title generated from the registry record
Registry title: Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Key facts
- Where
- Dijon, FranceSee the site
Where in France
- Chu Dijon BourgogneDijon, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Trial code
- NCT07256418
- Record updated
- 29 January 2026
- Original description
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.Read full original descriptionShow less
Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.
Inclusion: FOR PATIENTS WITH SCLERODERMA :; Person who has given written consent; Person with systemic scleroderma; FOR CONTROL PARTICIPANTS :; Person who has given written consent; Person undergoing plastic, cosmetic and reconstructive surgery.
Exclusion: Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases; FOR PATIENTS WITH SCLERODERMA :; Person not affiliated to or not benefiting from a social security scheme; Person subject to a legal protection measure (curatorship, guardianship); Person subject to a legal protection measure; An adult who is incapable or unable to give consent; Minors; FOR CONTROLLED PARTICIPANTS :; Person not affiliated to or not benefiting from a social security scheme; Person under legal protection (curatorship, guardianship); Person subject to a legal protection measure; An adult who is incapable or unable to give consent; Minors.